Comerica Bank decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 15.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 28,030 shares of the biotechnology company’s stock after selling 5,260 shares during the quarter. Comerica Bank owned 0.06% of United Therapeutics worth $3,489,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of UTHR. Sun Life Financial INC bought a new position in shares of United Therapeutics during the 2nd quarter worth about $198,000. Balasa Dinverno & Foltz LLC bought a new position in shares of United Therapeutics during the 3rd quarter worth about $260,000. Fox Run Management L.L.C. bought a new position in shares of United Therapeutics during the 2nd quarter worth about $269,000. IFM Investors Pty Ltd bought a new position in shares of United Therapeutics during the 3rd quarter worth about $301,000. Finally, HL Financial Services LLC increased its stake in United Therapeutics by 32.1% in the second quarter. HL Financial Services LLC now owns 2,711 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 658 shares during the period. Institutional investors own 93.69% of the company’s stock.

NASDAQ UTHR opened at $113.22 on Wednesday. The stock has a market capitalization of $5.30 billion, a P/E ratio of 10.40, a price-to-earnings-growth ratio of 28.36 and a beta of 1.23. United Therapeutics Co. has a twelve month low of $100.57 and a twelve month high of $152.55. The company has a current ratio of 4.32, a quick ratio of 4.05 and a debt-to-equity ratio of 0.09.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.23 by ($0.81). The business had revenue of $412.70 million during the quarter, compared to the consensus estimate of $378.22 million. United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The business’s revenue was down 7.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.69 EPS. As a group, research analysts anticipate that United Therapeutics Co. will post 14.28 earnings per share for the current fiscal year.

UTHR has been the topic of a number of analyst reports. Wedbush set a $253.00 target price on shares of United Therapeutics and gave the company a “buy” rating in a research note on Thursday, September 27th. HC Wainwright set a $95.00 target price on shares of United Therapeutics and gave the company a “hold” rating in a research note on Monday, August 13th. BidaskClub raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, September 18th. Cowen set a $106.00 target price on shares of United Therapeutics and gave the company a “hold” rating in a research note on Wednesday, October 31st. Finally, Credit Suisse Group upped their target price on shares of United Therapeutics from $103.00 to $105.00 and gave the company a “sell” rating in a research note on Monday. Two analysts have rated the stock with a sell rating, five have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $136.50.

In other United Therapeutics news, Director Christopher Causey sold 810 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $119.00, for a total transaction of $96,390.00. Following the sale, the director now directly owns 1,555 shares of the company’s stock, valued at $185,045. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 8.20% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2018/11/21/comerica-bank-reduces-stake-in-united-therapeutics-co-uthr.html.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Story: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.